Search results for " Second-Generation"

showing 10 items of 43 documents

Effects of chronic fluoxetine treatment on the rat somatosensory cortex: Activation and induction of neuronal structural plasticity

2009

Recent hypotheses support the idea that disruption of normal neuronal plasticity mechanisms underlies depression and other psychiatric disorders, and that antidepressant treatment may counteract these changes. In a previous report we found that chronic fluoxetine treatment increases the expression of the polysialylated form of the neural cell adhesion molecule (PSA-NCAM), a molecule involved in neuronal structural plasticity, in the somatosensory cortex. In the present study we intended to find whether, in fact, cell activation and neuronal structural remodeling occur in parallel to changes in the expression of this molecule. Using immunohistochemistry, we found that chronic fluoxetine trea…

MaleNeuronsNeuronal PlasticityDose-Response Relationship DrugGeneral NeuroscienceCentral nervous systemHippocampusSomatosensory CortexBiologySomatosensory systemRatsRats Sprague-Dawleymedicine.anatomical_structurenervous systemFluoxetineApical dendriteNeuroplasticitymedicineAnimalsAntidepressive Agents Second-GenerationNeural cell adhesion moleculeCell activationPrefrontal cortexNeuroscienceNeuroscience Letters
researchProduct

Chronic fluoxetine treatment alters the structure, connectivity and plasticity of cortical interneurons

2014

Novel hypotheses suggest that antidepressants, such as the selective serotonin reuptake inhibitor fluoxetine, induce neuronal structural plasticity, resembling that of the juvenile brain, although the underlying mechanisms of this reopening of the critical periods still remain unclear. However, recent studies suggest that inhibitory networks play an important role in this structural plasticity induced by fluoxetine. For this reason we have analysed the effects of a chronic fluoxetine treatment in the hippocampus and medial prefrontal cortex (mPFC) of transgenic mice displaying eGFP labelled interneurons. We have found an increase in the expression of molecules related to critical period pla…

MalePERINEURONAL NET EXPRESSIONTime FactorsDendritic spinePSA-NCAMCritical period plasticityHippocampusCell CountADULT BRAIN PLASTICITYTREATMENT INCREASESHippocampusMice0302 clinical medicinePharmacology (medical)Prefrontal cortexCerebral Cortex0303 health sciencesNeuronal PlasticitybiologyGlutamate DecarboxylaseMEDIAL PREFRONTAL CORTEXPOLYSIALIC ACIDmusculoskeletal neural and ocular physiologyPerineuronal net3. Good healthPsychiatry and Mental healthParvalbuminsmedicine.anatomical_structureCerebral cortexCELL-ADHESION MOLECULEAntidepressive Agents Second-GenerationDendritic SpinesGreen Fluorescent ProteinseducationMice TransgenicNerve Tissue ProteinsNeural Cell Adhesion Molecule L1Inhibitory postsynaptic potentialRAT HIPPOCAMPUS03 medical and health sciencesmedicineAnimalsPSA-NCAM EXPRESSION030304 developmental biologyPharmacologyperineuronal netsinterneuronsCENTRAL-NERVOUS-SYSTEMfluoxetine3112 NeurosciencesGene Expression Regulationnervous systemVesicular Glutamate Transport Protein 1Sialic Acidsbiology.proteinNeural cell adhesion moleculeNerve NetNeuroscience030217 neurology & neurosurgeryParvalbuminThe International Journal of Neuropsychopharmacology
researchProduct

Effects of acute and chronic maprotiline administration on inhibitory avoidance in male mice

2000

The effects of acute and chronic administration of maprotiline (5, 10 or 20 mg/kg, intraperitoneally) were assessed on inhibitory avoidance in male mice. Acute administration of maprotiline before training did not effect training phase latencies, but impaired performance (i.e. produced shorter latencies) in the test at doses of 5 and 20 mg/kg. When given after training, the drug did not modify test latencies at any of the doses used. Chronic administration for 21 days (interrupted 24 h before training) also shortened latencies in the test but not in training. An experiment on the acute effects of maprotiline on analgesia (determination of flinch and jump thresholds for increasing electric f…

MalePain ThresholdAnterograde amnesiaRatónInhibitory postsynaptic potentialDrug Administration ScheduleDevelopmental psychologyNorepinephrine (medication)MiceBehavioral NeuroscienceDrug toleranceThreshold of painAvoidance LearningReaction TimemedicineAnimalsMaprotilineDose-Response Relationship DrugBrainNeural InhibitionDrug ToleranceMaprotilineAnesthesiaMental RecallAntidepressive Agents Second-Generationmedicine.symptomPsychologyReuptake inhibitorInjections Intraperitonealmedicine.drugBehavioural Brain Research
researchProduct

Chronic antidepressant treatment induces contrasting patterns of synaptophysin and PSA-NCAM expression in different regions of the adult rat telencep…

2007

Structural modifications occur in the brain of severely depressed patients and they can be reversed by antidepressant treatment. Some of these changes do not occur in the same direction in different regions, such as the medial prefrontal cortex, the hippocampus or the amygdala. Differential structural plasticity also occurs in animal models of depression and it is also prevented by antidepressants. In order to know whether chronic fluoxetine treatment induces differential neuronal structural plasticity in rats, we have analyzed the expression of synaptophysin, a protein considered a marker of synaptic density, and the expression of the polysialylated form of the neural cell adhesion molecul…

MaleTelencephalonNeuropilNeuriteSynaptophysinHippocampusPrefrontal CortexNeural Cell Adhesion Molecule L1AmygdalaHippocampusRats Sprague-DawleyAnimal models of depressionFluoxetinemedicineAnimalsPharmacology (medical)Prefrontal cortexBiological PsychiatryPharmacologyNeuronal PlasticitybiologyCerebrumAmygdalaImmunohistochemistryAntidepressive AgentsRatsPsychiatry and Mental healthmedicine.anatomical_structurePhenotypenervous systemNeurologySynaptophysinbiology.proteinSialic AcidsAntidepressive Agents Second-GenerationNeural cell adhesion moleculeNeurology (clinical)NeuroscienceEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats.

2006

Recently, we described an advanced model of chronic social stress in male rats based on the resident intruder paradigm. In this model, rats subjected to daily social stress for 5 weeks showed behavioral changes resembling anhedonia and motivational deficits in humans. In the present study, male Wistar rats were subjected to 5 weeks of daily social defeat by an aggressive conspecific and concomitant treatment with the antidepressant drug fluoxetine (10 mg/kg) after the first week of stress. Compared with controls, rats exposed to chronic stress had significantly reduced locomotor and exploratory activity (rearing and sniffing) and diminished preference for sucrose solution. These effects wer…

Malemedicine.medical_specialtyBehavioral SymptomsMotor ActivitySocial defeat03 medical and health sciencesBehavioral NeuroscienceFood Preferences0302 clinical medicineSniffingInternal medicineFluoxetineAdrenal GlandsmedicineAnimalsChronic stressTestosteroneRats WistarTestosterone030304 developmental biologySocial stress0303 health sciencesFluoxetineAnalysis of VarianceBehavior AnimalBody WeightAnhedoniaRatsEndocrinologyExploratory BehaviorAntidepressantAntidepressive Agents Second-Generationmedicine.symptomPsychology030217 neurology & neurosurgeryStress Psychologicalmedicine.drugBehavioural brain research
researchProduct

Chronic Fluoxetine Treatment Increases the Expression of PSA-NCAM in the Medial Prefrontal Cortex

2006

Recent hypotheses suggest that changes in neuronal structure and connectivity may underlie the etiology of depression. The medial prefrontal cortex (mPFC) is affected by depression and shows neuronal remodeling during adulthood. This plasticity may be mediated by the polysialylated form of the neural cell adhesion molecule (PSA-NCAM), which is intensely expressed in the adult mPFC. As the expression of PSA-NCAM is increased by serotonin in other cerebral regions, antidepressants acting on serotonin reuptake may influence PSA-NCAM expression and thus counteract the effects of depression by modulating neuronal structural plasticity. Using immunohistochemistry, we have studied the relationship…

Malemedicine.medical_specialtyInterneuronFluorescent Antibody TechniquePrefrontal CortexCell CountNeural Cell Adhesion Molecule L1urologic and male genital diseasesSerotonergicRats Sprague-Dawleychemistry.chemical_compoundFluoxetineInternal medicinemedicineNeuropilAnimalsPrefrontal cortexNeurotransmitter5-HT receptorNeuronsPharmacologyAnalysis of VarianceRatsPsychiatry and Mental healthmedicine.anatomical_structureEndocrinologyGene Expression Regulationnervous systemchemistryReceptors SerotoninSialic AcidsAntidepressive Agents Second-GenerationNeural cell adhesion moleculeSerotoninPsychologyNeuroscienceNeuropsychopharmacology
researchProduct

Differential sensitivity to the effects of nicotine and bupropion in adolescent and adult male OF1 mice during social interaction tests.

2008

Few studies have compared the action of both nicotine (NIC) and bupropion (BUP), an antidepressant used to treat NIC dependence, on social and aggressive behavior at different ages. This study aims to determine whether these drugs produce differential effects in adolescent (postnatal day: 36–37) and adult (postnatal day: 65–66) mice that have been housed individually for 2 weeks in order to induce aggressive behavior. Mice received BUP (40, 20, or 10 mg/kg), NIC (1, 0.5, and 0.25 mg/kg as base), or vehicle earlier to a social interaction test. BUP (40 mg/kg) decreased social investigation and increased nonsocial exploration in both adolescent and adult mice. The same effects were also obser…

Malemedicine.medical_specialtyNicotineAdult malePhysiologyMice Inbred StrainsNicotineMiceArts and Humanities (miscellaneous)Age groupsDopamine Uptake InhibitorsStatistical significanceDevelopmental and Educational PsychologymedicineAnimalsNicotinic AgonistsPsychiatryPostnatal daySocial BehaviorBupropionGeneral PsychologyBupropionDose-Response Relationship DrugAge FactorsGroomingSocial relationAggressionSocial IsolationAntidepressantAntidepressive Agents Second-GenerationPsychologyAgonistic Behaviormedicine.drugAggressive behavior
researchProduct

Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.

2014

Background Bupropion is a dopamine and norepinephrine reuptake inhibitor approved for the treatment of depression and smoking cessation. According to the recently published reviews, it is a candidate for therapeutic drug monitoring (TDM) to improve therapeutic outcomes and reduce risks of intolerability or intoxication. In practice, however, the use of TDM is limited due to the chemical instability of bupropion. This investigation sought to determine if the major, active, and chemically stable metabolite 4-hydroxybupropion is a suitable measure to guide antidepressant drug therapy with bupropion. Methods 4-Hydroxybupropion serum levels were measured using a newly developed and validated hig…

Malemedicine.medical_specialtyUrologyNorepinephrine reuptake inhibitorPharmacokineticsmedicineHumansPharmacology (medical)BupropionChromatography High Pressure LiquidRetrospective StudiesPharmacologyBupropionDepressive Disordermedicine.diagnostic_testbusiness.industryTherapeutic effectHydroxybupropionMiddle AgedTherapeutic drug monitoringArea Under CurveClinical Global ImpressionAntidepressantAntidepressive Agents Second-GenerationFemalebusinessmedicine.drugHalf-LifeTherapeutic drug monitoring
researchProduct

Bupropion induces social anxiety in adolescent mice: Influence of housing conditions

2016

Abstract Background The antidepressant bupropion has received increasing attention as a pharmacological tool to treat addiction although little is known about its effects on social behaviour in adolescents. The present study aimed to evaluate if environmental housing conditions influence bupropion’s actions on social behaviour of adolescent mice. Methods Mice were either group- or individually housed for 2-weeks and then randomly divided into 2 cohorts: half of the mice remained in the initial housing condition and the other half were changed to isolated conditions for further 2-weeks. The following groups were compared: isolated/isolated (ISO/ISO), isolated/group-housed (ISO/GR), group-hou…

Malemedicine.medical_specialtymedia_common.quotation_subjectSocial behaviourAnxietyMice03 medical and health sciences0302 clinical medicinemedicineAnimalsSexual MaturationSocial BehaviorPsychiatryBupropionmedia_commonPharmacologyBupropionBehavior AnimalAddictionSocial anxietyGeneral MedicineHousing AnimalSocial relation030227 psychiatryAntidepressive Agents Second-GenerationAntidepressantPsychology030217 neurology & neurosurgerymedicine.drugPharmacological Reports
researchProduct

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.

2001

Therapeutic drug monitoring data of the new atypical neuroleptic drug olanzapine were used to study interactions with the selective serotonin reuptake inhibitors fluvoxamine and sertraline. The distribution of the ratio of concentration/daily dose (C/D; ng/mL per mg/d) of olanzapine was compared in three groups: patients treated with olanzapine (n = 134), patients treated with olanzapine plus fluvoxamine (n = 10) concomitantly, and patients treated with olanzapine plus sertraline (n = 21) concomitantly. No significant difference was seen between the olanzapine and the olanzapine plus sertraline groups. Patients receiving fluvoxamine in addition to olanzapine had C/D ratios that were in the …

OlanzapineAdultMaleFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsCytochrome P-450 Enzyme SystemSertralineMedicineHumansPharmacology (medical)Drug InteractionsAdverse effectChromatography High Pressure LiquidAgedPharmacologySertralineDepressive Disordermedicine.diagnostic_testbusiness.industryPirenzepineDrug interactionMiddle AgedLiverTherapeutic drug monitoringFluvoxamineOlanzapineAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic drug monitoring
researchProduct